Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: subsequently (81)

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Epcoritamab -Cycle 1 (Priming)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Priming) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

AtezolizumabSC Bevacizumab Carboplatin Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ATEZOLIZUMAB-SC-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Reg
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AtezolizumabSC-Bevacizumab-Carboplatin-Paclitaxel-Ver1.0.pdf

WDES report and action plan 2024

Description: Workforce Disability Equality Standard Annual Report 2024 1 Executive Summary The Workforce Disability Equality Standard (WDES)
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/UHS-WDES-report-and-action-plan-2024.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

Palliative care for people with CF - patient information

Description: We've written this factsheet to explain how the palliative care team can help and support you.
Url: /Media/UHS-website-2019/Patientinformation/Respiratory/Palliative-care-for-people-with-CF-2325-PIL.pdf

Flexible sigmoidoscopy (F1) aftercare advice - patient information

Description: This factsheet explains what to expect after having a flexible sigmoidoscopy.
Url: /Media/UHS-website-2019/Patientinformation/Endoscopy/Flexible-sigmoidoscopy-F1-aftercare-advice-680-PIL.pdf

Interstitial lung disease (ILD) clinical nurse specialist team - patient information

Description: This factsheet explains who the interstitial lung disease (ILD) clinical nurse specialist team are and how we can support you throughout
Url: /Media/UHS-website-2019/Patientinformation/Respiratory/Interstitial-lung-disease-ILD-clinical-nurse-specialist-team-3644-PIL.pdf

EC-DPH IV (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab IV)

Description: Please refer to the most up to date Bluteq eligibility criteria for pertuzumab and trastuzumab before prescribing.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-IV-Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

Docetaxel-Pertuzumab-Trastuzumab Ver 1.3

Description: Chemotherapy Protocol BREAST CANCER DOCETAXEL-PERTUZUMAB-TRASTUZUMAB This protocol may require funding Regimen • Bre
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-Pertuzumab-Trastuzumab.pdf

351 to 360 of 881

Previous … 34 35 36 37 38 … Next